Carcinoid and neuroendocrine tumours: Are we making any progress?

F. Murphy; W. J. Curry; N. Heaton; A. Stangou; M. Buxton-Thomas; J. K. Ramage

Carcinoid and neuroendocrine tumours: Are we making any progress?

F. Murphy, W. J. Curry, N. Heaton, A. Stangou, M. Buxton-Thomas, J. K. Ramage^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

Abstract

The investigation and management of neuroendocrine tumours is recognized to be a multidisciplinary process involving clinicians of many specialties. Chromogranin A has been accepted as a valuable immunohistopathological tissue marker for neuroendocrine tumours. The somatostatin analogues octreotide acetate and lanreotide are used to control symptoms and can improve quality of life. Surgery, transplantation, chemotherapy, embolisation and receptor targeted therapy all have a role to play in management. Given the longer length of survival of carcinoid patients, each is likely to need more than one type of treatment. These must be carefully chosen and the order in which they are offered to the patient carefully considered, rather than offering the treatment that is most readily available in that centre.

Original language	English
Pages (from-to)	63-68
Number of pages	6
Journal	CME Journal Gastroenterology, Hepatology and Nutrition
Volume	4
Issue number	2
Publication status	Published - 2001

Keywords

Carcinoid tumour
Chromogranins
Neuroendocrine tumours
Octreotide
Somatostatin receptor subtypes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{e5d747c792ed4c0fa848a4dc11faf4be,

title = "Carcinoid and neuroendocrine tumours: Are we making any progress?",

abstract = "The investigation and management of neuroendocrine tumours is recognized to be a multidisciplinary process involving clinicians of many specialties. Chromogranin A has been accepted as a valuable immunohistopathological tissue marker for neuroendocrine tumours. The somatostatin analogues octreotide acetate and lanreotide are used to control symptoms and can improve quality of life. Surgery, transplantation, chemotherapy, embolisation and receptor targeted therapy all have a role to play in management. Given the longer length of survival of carcinoid patients, each is likely to need more than one type of treatment. These must be carefully chosen and the order in which they are offered to the patient carefully considered, rather than offering the treatment that is most readily available in that centre.",

keywords = "Carcinoid tumour, Chromogranins, Neuroendocrine tumours, Octreotide, Somatostatin receptor subtypes",

author = "F. Murphy and Curry, {W. J.} and N. Heaton and A. Stangou and M. Buxton-Thomas and Ramage, {J. K.}",

year = "2001",

language = "English",

volume = "4",

pages = "63--68",

journal = "CME Journal Gastroenterology, Hepatology and Nutrition",

issn = "1367-9015",

publisher = "Rila Publications Ltd",

number = "2",

}

TY - JOUR

T1 - Carcinoid and neuroendocrine tumours

T2 - Are we making any progress?

AU - Murphy, F.

AU - Curry, W. J.

AU - Heaton, N.

AU - Stangou, A.

AU - Buxton-Thomas, M.

AU - Ramage, J. K.

PY - 2001

Y1 - 2001

N2 - The investigation and management of neuroendocrine tumours is recognized to be a multidisciplinary process involving clinicians of many specialties. Chromogranin A has been accepted as a valuable immunohistopathological tissue marker for neuroendocrine tumours. The somatostatin analogues octreotide acetate and lanreotide are used to control symptoms and can improve quality of life. Surgery, transplantation, chemotherapy, embolisation and receptor targeted therapy all have a role to play in management. Given the longer length of survival of carcinoid patients, each is likely to need more than one type of treatment. These must be carefully chosen and the order in which they are offered to the patient carefully considered, rather than offering the treatment that is most readily available in that centre.

AB - The investigation and management of neuroendocrine tumours is recognized to be a multidisciplinary process involving clinicians of many specialties. Chromogranin A has been accepted as a valuable immunohistopathological tissue marker for neuroendocrine tumours. The somatostatin analogues octreotide acetate and lanreotide are used to control symptoms and can improve quality of life. Surgery, transplantation, chemotherapy, embolisation and receptor targeted therapy all have a role to play in management. Given the longer length of survival of carcinoid patients, each is likely to need more than one type of treatment. These must be carefully chosen and the order in which they are offered to the patient carefully considered, rather than offering the treatment that is most readily available in that centre.

KW - Carcinoid tumour

KW - Chromogranins

KW - Neuroendocrine tumours

KW - Octreotide

KW - Somatostatin receptor subtypes

UR - http://www.scopus.com/inward/record.url?scp=0035687466&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0035687466

SN - 1367-9015

VL - 4

SP - 63

EP - 68

JO - CME Journal Gastroenterology, Hepatology and Nutrition

JF - CME Journal Gastroenterology, Hepatology and Nutrition

IS - 2

ER -

Carcinoid and neuroendocrine tumours: Are we making any progress?

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this